Compugen Strikes Strategic Deal with AstraZeneca Worth up to $90 Million Compugen Ltd. has successfully monetized a portion of its future royalty rights with AstraZeneca, securing $90 million to enhance its immunotherapy pipeline.

Compugen Strikes Strategic Deal with AstraZeneca Worth up to $90 Million #Israel #AstraZeneca #Compugen #Holon #Rilvegostomig